Biohacking Market Report 2025: Set to Surge from $24.5 Billion in 2024 to $111.3 Billion by 2034 as Preventive Healthcare and Wearables Gain Ground
Prominent Players Like Neuralink, Oura Health, WHOOP, Cyborg Nest, and Muse are Disrupting the Industry
Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Biohacking Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.The Global Biohacking Market was valued at USD 24.5 billion in 2024 and is estimated to grow at a CAGR of 16.5% to reach USD 111.3 billion by 2034.
Biohacking is emerging as a transformative trend at the intersection of science, technology, and self-improvement. It offers individuals the tools to take control of their physical and mental well-being through personalized interventions. From nutrition and sleep optimization to genetic engineering and implantable devices, the spectrum of biohacking is broad and constantly evolving. What's fueling this movement is the growing consumer shift toward preventive healthcare and performance optimization.People are no longer waiting for symptoms to act - they're using real-time data and advanced health tools to preempt issues and enhance quality of life. As healthcare becomes more individualized, demand is rising for innovative solutions that allow users to monitor, analyze, and fine-tune their biological functions on their own terms. The rise in chronic illnesses, increasing healthcare costs, and growing access to affordable wearable tech are accelerating the adoption of biohacking practices worldwide. This trend is further amplified by social media, online health communities, and DIY biology groups that encourage experimentation and knowledge sharing.The wearable technology segment generated USD 7 billion in 2024 and is projected to grow at a CAGR of 16.8% through 2034. Users are increasingly turning to smartwatches, fitness bands, and smart rings to track vital metrics like sleep cycles, heart rate, brain activity, and daily performance levels. These devices offer personalized insights in real-time, helping users identify trends, make informed decisions, and tweak their daily routines for better health outcomes. By providing continuous tracking and actionable feedback, wearable tech is becoming an essential tool for individuals looking to upgrade their health and wellness journeys. The ability to detect early changes in physiological or cognitive states gives users the power to intervene early, adjust habits, and stay ahead of potential health concerns.In terms of application, the diagnosis and treatment segment generated USD 7 billion and held a 28.4% market share in 2024. The growing global burden of chronic conditions like diabetes and cardiovascular disease is pushing users to seek more control over their health. Through advanced sensors and home-based monitoring tools, biohackers can track glucose levels, hormone fluctuations, blood pressure, and more. This real-time data access supports early detection, encourages preventative care, and reduces dependency on traditional healthcare visits. It empowers users to make behavior and lifestyle changes based on precise health data, significantly lowering long-term health risks.The United States Biohacking Market generated USD 7.9 billion in 2023. The country's high incidence of chronic conditions continues to drive demand for advanced biohacking tools. Cutting-edge research from healthcare institutions, biotech firms, and startups fuels innovation across the space. Companies are increasingly focused on disease prevention, personalized health solutions, and next-gen technology development.Some of the prominent players in the Global Biohacking Industry include Neuralink, Oura Health Oy, WHOOP, Cyborg Nest, Muse, Cronometer, OpenBCI, Senseonics, Synbiota, Thync Global, Viome Life Science, Fitbit, TrackMyStack, Nuanic, OsteoStrong, and Proteus Digital Health. To stay competitive, these companies are heavily investing in research and development, launching next-gen wearable devices, expanding their product lines, and integrating AI-driven health platforms. Strategic partnerships, market expansion, and digital innovation remain key to engaging consumers and elevating brand value in this fast-growing space.Comprehensive Market Analysis and Forecast
Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
Competitive landscape with Porter's Five Forces and PESTEL analysis
Market size, segmentation, and regional forecasts
In-depth company profiles, business strategies, financial insights, and SWOT analysis
Key Attributes
Report Attribute
Details
No. of Pages
132
Forecast Period
2024-2034
Estimated Market Value (USD) in 2024
$24.5 Billion
Forecasted Market Value (USD) by 2034
$111.3 Billion
Compound Annual Growth Rate
16.5%
Regions Covered
Global
Key Topics CoveredChapter 1 Methodology and Scope1.1 Market scope and definitions1.2 Research design1.2.1 Research approach1.2.2 Data collection methods1.3 Base estimates and calculations1.3.1 Base year calculation1.3.2 Key trends for market estimation1.4 Forecast model1.5 Primary research and validation1.5.1 Primary sources1.5.2 Data mining sourcesChapter 2 Executive Summary2.1 Industry 360 degree synopsisChapter 3 Industry Insights3.1 Industry ecosystem analysis3.2 Industry impact forces3.2.1 Growth drivers3.2.1.1 Rising prevalence of chronic diseases3.2.1.2 Technological advancements in biohacking3.2.1.3 Growing demand for wearable devices3.2.1.4 Increasing health awareness3.2.2 Industry pitfalls and challenges3.2.2.1 High costs of advanced devices3.2.2.2 Lack of skilled professionals3.3 Growth potential analysis3.4 Regulatory landscape3.5 Technological landscape3.6 Future market trends3.7 Porter's analysis3.8 PESTEL analysisChapter 4 Competitive Landscape, 20244.1 Introduction4.2 Company market share analysis4.3 Company matrix analysis4.4 Competitive analysis of major market players4.5 Competitive positioning matrix4.6 Strategy dashboardChapter 5 Market Estimates and Forecast, By Product, 2021-2034 ($ Mn)5.1 Key trends5.2 Wearable5.2.1 Wearable neurotech5.2.2 Oura ring5.2.3 Muse headband5.2.4 Other wearables5.3 Implants5.3.1 Blood test implant5.3.2 Circadia implant5.3.3 Cardiac and vascular implants5.3.4 Other implants5.4 Gene modification kits5.5 Smart drugs5.6 Supplements5.7 Mobile apps5.8 Other productsChapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)6.1 Key trends6.2 Synthetic biology6.3 Genetic engineering6.4 Forensic science6.5 Diagnosis and treatment6.6 Drug testing6.7 Other applicationsChapter 7 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)7.1 Key trends7.2 Hospitals and clinics7.3 Pharmaceutical and biotechnology companies7.4 Forensic laboratories7.5 Academic and research institutesChapter 8 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)8.1 Key trends8.2 North America8.2.1 U.S.8.2.2 Canada8.3 Europe8.3.1 Germany8.3.2 UK8.3.3 France8.3.4 Spain8.3.5 Italy8.3.6 Netherlands8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Australia8.4.5 South Korea8.5 Latin America8.5.1 Brazil8.5.2 Mexico8.5.3 Argentina8.6 Middle East and Africa8.6.1 South Africa8.6.2 Saudi Arabia8.6.3 UAEChapter 9 Company Profiles9.1 Cyborg Nest9.2 Cronometer9.3 Fitbit9.4 Muse9.5 Nuanic9.6 Neuralink9.7 OpenBCI9.8 OsteoStrong9.9 Oura Health Oy9.10 Proteus Digital Health9.11 TrackMyStack9.12 Thync Global9.13 Synbiota9.14 Senseonics9.15 Viome Life Science9.16 WHOOPFor more information about this report visit https://www.researchandmarkets.com/r/gnewa3
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Circle stock gains 7%, extends gains for third day in a row since blockbuster IPO
Circle's (CRCL) stock surged for a third day in a row on Monday following its blockbuster IPO last week. Shares of the stablecoin issuer jumped as much as 15% before paring gains to close at $115 per share, a premium of 270% above its debut IPO price of $31. The surge builds on gains from the previous two trading days, including an intraday surge of over 200% last Thursday shortly after the company's highly anticipated market debut. Circle's IPO success comes amid bullish momentum in the crypto space, including the Trump administration's push for a friendly framework for cryptocurrencies, the president's business involvement in the space, and legislation in Congress that would regulate stablecoins. "Having a crypto-friendly administration, the legislation ... plus the fact that larger financial institutions are considering launching their own coins, these are all tailwinds and votes of confidence in the stablecoin market," EquityZen head of market insight Brianne Lynch told Yahoo Finance last Thursday. Circle had previously attempted to go public via a SPAC deal in 2021 but ultimately shelved the plan a year later. Circle is the issuer of the stablecoin USDC (USDC-USD), which is backed by the dollar. The company had $60 billion worth of the token in circulation at the end of the first quarter. Circle is the second-largest stablecoin issuer on the market, trailing only Tether, which has nearly $150 billion in circulation. The company generates the bulk of its revenue through "reserve income" — profits earned from the cash reserves backing the USDC stablecoins. Publicly traded companies have been increasing their exposure to digital assets, with some shifting their strategies to emulate Strategy's (MSTR) bitcoin treasury model. Bitcoin (BTC-USD) recently surged to all-time highs above $110,000. On Monday, bitcoin traded near $107,000 per token. Click here for in-depth analysis of the latest stock market news and events moving stock prices
Yahoo
an hour ago
- Yahoo
TON Surges 2.7% on Massive Volume Before Sharp Reversal
TON-USD climbed from $3.156 to $3.24, showing remarkable strength with a 2.66% gain during a powerful breakout supported by high trading volume, according to CoinDesk Research's technical analysis model. The cryptocurrency found support near the $3.19-$3.20 zone, forming a potential short-term double bottom pattern that could serve as a level for continuation of the broader uptrend. The CoinDesk 20 — an index of the top 20 cryptocurrencies by market capitalization, excluding stablecoins, memecoins and exchange coins — is up 1.1% in the last 24 hours. Technical Analysis • TON-USD demonstrated remarkable strength over the 24-hour period, climbing from $3.15 to a peak of $3.24, representing a range of $0.08 (2.66%). • The price action formed a clear uptrend with higher lows and higher highs, culminating in a powerful breakout with the highest volume of the period (5.46M). • Key support established at $3.15-$3.16 held firmly during multiple tests, while resistance at $3.20 was decisively broken on high volume, confirming the bullish momentum. • The subsequent consolidation near $3.20 after reaching the $3.24 high suggests profit-taking but maintains most gains, indicating potential for continued upward movement if volume support persists. • In the last hour, TON-USD experienced significant volatility, initially continuing its upward momentum to reach a peak of $3.23, representing a 0.5% gain. • This bullish trend reversed sharply, with price cascading down to $3.19, marking a 2.7% decline from the peak. • The sell-off was accompanied by high volume, indicating strong distribution. • The price found support near $3.19 and staged a modest recovery to close at $3.2, forming a potential double bottom pattern. • This price action suggests profit-taking following the earlier breakout, with the $3.19-$3.20 zone now established as a critical support level for potential continuation of the broader uptrend. Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Nontuberculous Mycobacterial (NTM) Diagnostic Market to Reach USD 3,261.1 million By 2032, Growing At An 6.64% CAGR
PUNE, India, June 9, 2025 /PRNewswire/ -- According to the latest research by Credence Research, the global Nontuberculous Mycobacterial (NTM) Diagnostic Market was valued at USD 1,814.8 million in 2023 and is projected to reach USD 3,261.1 million by 2032, growing at a compound annual growth rate (CAGR) of 6.64% during the forecast period. The rising incidence of NTM infections, especially among immunocompromised patients and individuals with chronic pulmonary conditions, is a primary factor driving market demand. Technological advancements in molecular diagnostics and imaging techniques are significantly enhancing detection accuracy and speed, leading to faster diagnosis and improved clinical outcomes. Healthcare providers are increasingly adopting advanced diagnostic platforms to address the complexities of identifying NTM species, which often mimic other pulmonary disorders. This shift is further supported by growing awareness of NTM-related diseases and stronger clinical guidelines for early screening and diagnosis. Expanding healthcare infrastructure across emerging markets, coupled with increased investments in R&D by diagnostics companies, is expected to accelerate market expansion over the coming years. Browse the report and understand how it can benefit your business strategy- Key Growth Determinants: Nontuberculous Mycobacterial (NTM) Diagnostic Market The growth of the NTM Diagnostic Market is primarily driven by the rising global prevalence of NTM infections, particularly among the aging population and individuals with underlying lung conditions such as COPD, bronchiectasis, and cystic fibrosis. As awareness of these infections increases among healthcare professionals, the demand for timely and accurate diagnostic solutions is expanding. This trend is supported by an uptick in hospital admissions and outpatient consultations related to unexplained pulmonary symptoms, where NTM is an emerging differential diagnosis. Another key growth determinant is the rapid advancement in diagnostic technologies. Innovations in molecular diagnostics, PCR-based assays, and next-generation sequencing (NGS) are enabling faster, more precise identification of various NTM species, overcoming the limitations of traditional culture methods. Furthermore, increased funding for infectious disease research and growing collaborations between public health organizations and diagnostic manufacturers are creating favorable conditions for product development and market penetration. The rising implementation of clinical guidelines recommending early testing for at-risk populations is also bolstering the adoption of advanced NTM diagnostics globally. Key Growth Barriers: Nontuberculous Mycobacterial (NTM) Diagnostic Market Limited Awareness and MisdiagnosisMany clinicians and patients remain unaware of NTM infections, which often mimic tuberculosis or other chronic pulmonary conditions. This lack of awareness leads to frequent misdiagnosis or delayed testing, particularly in settings with limited diagnostic infrastructure. Diagnostic Complexity and InaccessibilityAccurate identification of NTM species is essential for effective treatment, but traditional culture methods are time-consuming and may lack sensitivity. Advanced molecular diagnostic tools, though more effective, are not widely accessible in many regions, especially in developing markets. Resource Constraints in Healthcare FacilitiesComprehensive NTM diagnostics require specialized laboratory equipment, trained personnel, and standardized testing protocols. Many healthcare systems, especially in low- and middle-income countries, face limitations in implementing such advanced diagnostics. Regulatory and Reimbursement ChallengesNavigating regulatory approval for new diagnostic tools can be time-consuming and costly. In addition, limited reimbursement policies for advanced NTM diagnostic tests discourage healthcare providers from adopting innovative solutions. Segmentation Based on Diagnostic Method: Nucleic Acid Amplification Tests (NAAT) Microscopy Culture-based Methods Biochemical Tests Immunological Tests PCR Others Based on Infection Type: Pulmonary Cutaneous Disseminated Gastrointestinal Others Based on End-User: Hospitals & Clinics Diagnostic Laboratories Others Based on region North America Europe Asia Pacific Latin America Middle East & Africa Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today - Regional Analysis: Nontuberculous Mycobacterial (NTM) Diagnostic Market North America holds the largest share of the global NTM Diagnostic Market, accounting for approximately 39% of total revenue in 2023. This dominance is driven by advanced healthcare infrastructure, widespread use of molecular diagnostic technologies, and high awareness of NTM-related diseases. The presence of major diagnostic companies and strong R&D funding further support market growth in the United States and Canada. Europe follows with around 27% of the market share. Countries like Germany, the UK, and France are key contributors, supported by growing recognition of NTM infections, aging populations, and well-established public health systems. Increased focus on early diagnosis and the adoption of advanced testing tools continue to fuel regional demand. Asia-Pacific accounts for roughly 23% of the global market. Rapid improvements in healthcare infrastructure, growing patient awareness, and increased investments in diagnostic technologies are propelling growth in China, Japan, South Korea, and India. Partnerships between international diagnostic firms and regional players are expanding access to accurate NTM testing. Latin America represents about 6% of the market, led by Brazil, Mexico, and Argentina. Market growth is supported by public health campaigns and improved diagnostic capabilities, though infrastructure disparities in remote areas remain a challenge. Middle East & Africa comprise the smallest share, approximately 5% in 2023. While diagnostic capacity remains limited in many parts of the region, targeted investments in laboratory services and healthcare modernization—especially in the GCC and South Africa—are gradually improving market potential. Credence Research's Competitive Landscape Analysis Credence Research's Competitive Landscape Analysis presents a clear and focused view of key industry players in the NTM diagnostic segment with a spotlight on strategic strengths and market positioning: Credence Research identifies a handful of dominant multinational diagnostics firms—Thermo Fisher Scientific Inc., F. Hoffmann‑La Roche Ltd, Becton, Dickinson & Company (BD), and bioMérieux SA—as frontrunners in the global NTM diagnostic market. These companies differentiate themselves via wide-ranging product portfolios that encompass both molecular and immunological diagnostic tools. They cater to centralized laboratory settings and decentralized testing environments, ensuring flexibility across different healthcare infrastructures. Their strong investment in R&D, global distribution networks, and robust service support contribute to their sustained competitive edge and rapid product adoption. Through its analysis, Credence Research highlights how these industry leaders are not only maintaining market dominance but also expanding access to advanced NTM diagnostic solutions via collaborations, innovative product development, and targeted regional strategies—positioning themselves to capitalise on the projected market growth. Tailor the report to align with your specific business needs and gain targeted insights. Request Full Report Here- Key Player Analysis Thermo Fisher Scientific Inc Hoffmann-La Roche Ltd Becton, Dickinson and Company (BD) bioMérieux SA Bruker Corporation SD Biosensor Bioneer Seegene Inc. Recent Industry Developments June 2025 – Thermo Fisher Scientific introduced two advanced mass spectrometry instruments—the Orbitrap Astral Zoom and Orbitrap Excedion Pro—during the ASMS conference. Designed primarily for proteomics and biopharma applications, these systems deliver enhanced speed and sensitivity, significantly advancing the analysis of complex biological samples. Their improved resolution and throughput have potential applications in infectious disease diagnostics, including NTM-related testing. December 2024 – Shanghai MicuRx Pharmaceutical ( announced that the U.S. FDA granted Orphan Drug Designation (ODD) to its investigational anti-infective drug MRX-5 for the treatment of NTM infections, representing a significant step in developing targeted therapies for this condition. September 2023 – QIAGEN entered a strategic partnership with a major South Asian healthcare provider to integrate its proprietary diagnostics into regional laboratories, enhancing capabilities for detecting and managing NTM infections. August 2023 – bioMérieux expanded its infectious disease portfolio through the acquisition of a biotech company specializing in NTM diagnostics. July 2023 – Hologic, Inc. secured regulatory approval for a new diagnostic test specifically developed to identify NTM infections, reinforcing its commitment to infectious disease diagnostics. January 2022 – Gaelan Medical Trade LLC partnered with RedHill Biopharma Ltd. to distribute Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. Though primarily approved for H. pylori, its components hold relevance in mycobacterial infection strategies. February 2021 – Koninklijke Philips N.V. completed the acquisition of BioTelemetry, Inc., a leader in remote monitoring and diagnostics, potentially expanding future integration of infectious disease tracking technologies. Reasons to Purchase this Report: Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion). Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region. Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years. Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning. Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions. Benefit from Porter's Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics. Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years. Browse the report and understand how it can benefit your business strategy - Discover additional reports tailored to your industry needs Ocular Drug Delivery System Market - Pharma Grade Synthetic Camphor Market - Topical Drug Delivery Market - Lidocaine Market - Dermatology and Eye Care Services Market - Metabolism Assays Market - Dental Implantology Drill Bit Market - Dental Implantology Drill Bit Market - Tetrabenazine Market - Follow Us: About Us: Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. Contact Us Mitul DeanTower C-1105 , S 25, Akash Tower,Vishal Nahar, Pimple Nilakh, Haveli,Pune – 411027, Indiasales@ Logo - View original content to download multimedia: SOURCE Credence Research Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
